23 studies found for:    siltuximab
Show Display Options
Rank Status Study
1 Completed A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors
Conditions: Ovarian Neoplasms;   Pancreatic Neoplasms;   Colorectal Neoplasms;   Head and Neck Neoplasms;   Lung Neoplasms
Intervention: Drug: CNTO 328; Anti-interleukin-6 monoclonal antibody
2 Completed
Has Results
A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients
Condition: Multiple Myeloma
Interventions: Drug: Siltuximab11 mg/kg;   Drug: Siltuximab 8.3 mg/kg or 11 mg/kg;   Drug: Velcade (bortezomib);   Drug: Melphalan;   Drug: Prednisone
3 Completed A Study to Assess the Safety and Pharmacokinetics of a Single Intravenous Administration of CNTO 328 Derived From 2 Different Cell Lines in Healthy Participants
Condition: Healthy
Interventions: Drug: CNTO 328 (Sp2/0-derived);   Drug: CNTO 328 (CHO-derived);   Drug: Placebo
4 Active, not recruiting A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease
Condition: Multicentric Castleman's Disease
Intervention: Drug: Siltuximab
5 Completed
Has Results
Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)
Condition: Myeloma
Interventions: Drug: Lenalidomide;   Drug: Bortezomib;   Drug: Siltuximab;   Drug: Dexamethasone;   Behavioral: Questionnaires
6 Terminated A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Siltuximab
7 Withdrawn A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Placebo, Velcade and dexamethasone;   Biological: Siltuximab, Velcade and dexamethasone
8 Not yet recruiting Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis
Conditions: Myelofibrosis;   Polycythemia Vera;   Primary Myelofibrosis;   Thrombocytopenia
Interventions: Procedure: Bone Marrow Aspiration and Biopsy;   Other: Laboratory Biomarker Analysis;   Biological: Siltuximab
9 Active, not recruiting
Has Results
A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease
Condition: Multicentric Castleman's Disease
Interventions: Drug: Siltuximab;   Drug: Placebo;   Drug: Best Supportive Care (BSC)
10 Completed An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Biological: Siltuximab;   Drug: Dexamethasone
11 Terminated
Has Results
A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome
Interventions: Drug: Siltuximab;   Drug: Placebo;   Drug: Best supportive care (BSC)
12 Terminated
Has Results
A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)
Condition: Cancer, Prostate
Interventions: Drug: Mitoxantrone;   Drug: Siltuximab;   Drug: Prednisone
13 Active, not recruiting
Has Results
A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Biological: Siltuximab;   Drug: Bortezomib;   Drug: Placebo;   Drug: Dexamethasone
14 Completed A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma
Conditions: Monoclonal Gammopathy of Undetermined Significance;   Multiple Myeloma;   Plasma Cell Neoplasm
Intervention: Biological: Siltuximab
15 Completed A Study of CNTO 328 in Subjects With Metastatic Renal Cell Carcinoma
Condition: Carcinoma, Renal Cell
Intervention: Drug: CNTO 328
16 Recruiting Modulation of STAT3 Signaling With Siltuximab in Type 1 Diabetes
Condition: Type 1 Diabetes
Intervention: Drug: Siltuximab
17 Active, not recruiting A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Condition: High-risk Smoldering Multiple Myeloma
Interventions: Drug: Siltuximab;   Drug: Placebo
18 Recruiting Siltuximab in Schizophrenia
Conditions: Schizophrenia;   Psychotic Disorders
Interventions: Drug: Siltuximab;   Drug: normal saline
19 Completed A Study of CNTO 328 in Patients With Metastatic Hormone-Refractory Prostate Cancer
Condition: Prostatic Neoplasms
Interventions: Drug: CNTO 328;   Drug: Docetaxel
20 Completed A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease
Conditions: Lymphoma, Non-Hodgkin;   Multiple Myeloma;   Giant Lymph Node Hyperplasia
Intervention: Drug: CNTO 328

   Previous Page Studies Shown (1-20) Next Page (21-23) Show next page of results    Last Page
Indicates status has not been verified in more than two years